跳至主要内容
临床试验/NCT01207635
NCT01207635已完成不适用

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2002年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
42
试验地点
1
主要终点
Number of Patients with Antiproliferative Effects of Arimidex

研究概览

简要总结

The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients.

Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Patient must have a history of breast cancer.
  • Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.
  • Patient must be willing to undergo a duct lavage.
  • Patient must sign an Informed Consent.

排除标准

  • 未提供

结局指标

主要结局

Number of Patients with Antiproliferative Effects of Arimidex

时间窗: Study duration 4 years

Biomarker modulation study on effects of Armimidex in ductal lavage fluid from evaluable epithelial cells specimen.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验